Fiduciary Family Office LLC Acquires 2,702 Shares of IQVIA Holdings Inc. $IQV

Fiduciary Family Office LLC grew its holdings in IQVIA Holdings Inc. (NYSE:IQV) by 78.3% in the third quarter, according to the company in its most recent Form 13F filing with the SEC. The institutional investor owned 6,153 shares of the medical research company’s stock after buying an additional 2,702 shares during the quarter. Fiduciary Family Office LLC’s holdings in IQVIA were worth $1,169,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds have also added to or reduced their stakes in IQV. Verdence Capital Advisors LLC acquired a new stake in IQVIA in the second quarter worth $3,612,000. Amundi increased its position in shares of IQVIA by 46.3% in the 2nd quarter. Amundi now owns 1,279,817 shares of the medical research company’s stock valued at $210,722,000 after buying an additional 405,250 shares in the last quarter. Act Two Investors LLC acquired a new stake in IQVIA during the 2nd quarter worth $26,528,000. Diversified Trust Co lifted its holdings in IQVIA by 57.2% during the third quarter. Diversified Trust Co now owns 42,579 shares of the medical research company’s stock worth $8,087,000 after acquiring an additional 15,487 shares in the last quarter. Finally, Oregon Public Employees Retirement Fund increased its holdings in shares of IQVIA by 37.1% in the third quarter. Oregon Public Employees Retirement Fund now owns 19,463 shares of the medical research company’s stock worth $3,697,000 after acquiring an additional 5,271 shares in the last quarter. Institutional investors and hedge funds own 89.62% of the company’s stock.

IQVIA Stock Down 1.3%

NYSE:IQV opened at $238.03 on Friday. IQVIA Holdings Inc. has a twelve month low of $134.65 and a twelve month high of $247.04. The company has a quick ratio of 0.70, a current ratio of 0.70 and a debt-to-equity ratio of 2.03. The stock’s 50 day moving average price is $227.30 and its two-hundred day moving average price is $203.34. The firm has a market capitalization of $40.54 billion, a price-to-earnings ratio of 32.65, a price-to-earnings-growth ratio of 2.42 and a beta of 1.36.

IQVIA (NYSE:IQV) last posted its quarterly earnings results on Tuesday, October 28th. The medical research company reported $3.00 earnings per share (EPS) for the quarter, topping the consensus estimate of $2.98 by $0.02. IQVIA had a net margin of 8.07% and a return on equity of 30.70%. The firm had revenue of $4.10 billion for the quarter, compared to analyst estimates of $4.07 billion. During the same period in the prior year, the firm posted $2.84 earnings per share. The company’s quarterly revenue was up 5.2% compared to the same quarter last year. IQVIA has set its FY 2025 guidance at 11.850-11.950 EPS. Equities research analysts expect that IQVIA Holdings Inc. will post 10.84 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

Several brokerages recently issued reports on IQV. Stifel Nicolaus boosted their price objective on IQVIA from $234.00 to $254.00 and gave the company a “buy” rating in a research report on Wednesday, October 29th. Weiss Ratings reaffirmed a “hold (c)” rating on shares of IQVIA in a research note on Wednesday, October 8th. BMO Capital Markets started coverage on shares of IQVIA in a report on Thursday, November 13th. They set an “outperform” rating and a $260.00 price objective on the stock. Citigroup lifted their price target on IQVIA from $200.00 to $230.00 and gave the company a “neutral” rating in a research note on Wednesday, October 29th. Finally, Barclays set a $230.00 price target on IQVIA in a report on Monday, December 15th. Two investment analysts have rated the stock with a Strong Buy rating, thirteen have given a Buy rating and six have given a Hold rating to the company’s stock. According to data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus target price of $249.19.

Insider Buying and Selling

In other IQVIA news, insider Eric Sherbet sold 4,000 shares of the business’s stock in a transaction that occurred on Wednesday, October 29th. The stock was sold at an average price of $219.70, for a total transaction of $878,800.00. Following the transaction, the insider owned 27,108 shares of the company’s stock, valued at $5,955,627.60. The trade was a 12.86% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Insiders own 1.60% of the company’s stock.

IQVIA Profile

IQVIA (NYSE: IQV) is a global provider of advanced analytics, technology solutions and contract research services to the life sciences industry. The company combines clinical research capabilities with large-scale health data and analytics to support drug development, regulatory reporting, commercial strategy and real‑world evidence generation. IQVIA traces its current form to the combination of Quintiles and IMS Health announced in 2016 and subsequently rebranded as IQVIA, bringing together long-established clinical research operations and extensive healthcare information assets.

IQVIA’s principal activities include outsourced clinical development services (acting as a contract research organization for phases I–IV), real‑world evidence and observational research, regulatory and safety services, and a suite of technology platforms that enable data integration, analytics and operational management.